Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) Increase (Decrease) in Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

Arcus Biosciences, Inc. Increase (Decrease) in Accounts Payable

Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Accounts Payable of -$8.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05

  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$5.00M, a 162.50% decline year-over-year.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$3.00M, a 200.00% decline year-over-year.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $13.00M.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was $24.00M, a 700.00% increase from fiscal 2024.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was $3.00M.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$1.00M, a 112.50% decline from fiscal 2022.
  • Arcus Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was $8.00M.
Period endIncrease (Decrease) in Accounts Payable 3 monthIncrease (Decrease) in Accounts Payable 3 month as first filedIncrease (Decrease) in Accounts Payable 6 monthIncrease (Decrease) in Accounts Payable 6 month as first filedIncrease (Decrease) in Accounts Payable 9 monthIncrease (Decrease) in Accounts Payable 9 month as first filedIncrease (Decrease) in Accounts Payable 12 monthIncrease (Decrease) in Accounts Payable 12 month as first filed
2026-06-30-$5.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$8.00M
10-Q · filed 2026-08-05
-$8.00M
derived: sum of 3 quarters · filed 2026-08-05
$5.00M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$3.00M
10-Q · filed 2026-05-05
-$3.00M
derived: sum of 2 quarters · filed 2026-05-05
$10.00M
derived: sum of 3 quarters · filed 2026-05-05
$18.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$13.00M
derived: sum of 2 quarters · filed 2026-02-25
$21.00M
derived: sum of 3 quarters · filed 2026-08-05
$24.00M
10-K · filed 2026-02-25
2025-09-30$13.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$21.00M
derived: sum of 2 quarters · filed 2026-08-05
$24.00M
10-Q · filed 2025-10-28
$29.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$8.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$11.00M
10-Q · filed 2026-08-05
$16.00M
derived: sum of 3 quarters · filed 2026-08-05
$15.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$3.00M
10-Q · filed 2026-05-05
$8.00M
derived: sum of 2 quarters · filed 2026-05-05
$7.00M
derived: sum of 3 quarters · filed 2026-05-05
$7.00M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$4.00M
derived: sum of 2 quarters · filed 2026-02-25
$4.00M
derived: sum of 3 quarters · filed 2026-02-25
$3.00M
10-K · filed 2026-02-25
2024-09-30-$1.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
-$1.00M
derived: sum of 2 quarters · filed 2025-10-28
-$2.00M
10-Q · filed 2025-10-28
$0.00
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$1.00M
10-Q · filed 2025-08-06
$1.00M
derived: sum of 3 quarters · filed 2026-02-25
$7.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31-$1.00M
10-Q · filed 2025-05-06
$1.00M
derived: sum of 2 quarters · filed 2026-02-25
$7.00M
derived: sum of 3 quarters · filed 2026-02-25
-$12.00M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$8.00M
derived: sum of 2 quarters · filed 2026-02-25
-$11.00M
derived: sum of 3 quarters · filed 2026-02-25
-$1.00M
10-K · filed 2026-02-25
2023-09-30$6.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$13.00M
derived: sum of 2 quarters · filed 2024-11-06
-$3.00M
10-Q · filed 2024-11-06
$5.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30-$19.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$9.00M
10-Q · filed 2024-08-08
-$1.00M
derived: sum of 3 quarters · filed 2025-02-25
-$13.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31$10.00M
10-Q · filed 2024-05-08
$18.00M
derived: sum of 2 quarters · filed 2025-02-25
$6.00M
derived: sum of 3 quarters · filed 2025-02-25
$10.00M
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31$8.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
-$4.00M
derived: sum of 2 quarters · filed 2025-02-25
$0.00
derived: sum of 3 quarters · filed 2025-02-25
$8.00M
10-K · filed 2025-02-25
2022-09-30-$12.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$8.00M
derived: sum of 2 quarters · filed 2023-11-07
$0.00
10-Q · filed 2023-11-07
-$54.00K
10-Q · filed 2022-11-02
$424.00K
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30$4.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$12.00M
10-Q · filed 2023-08-07
$12.10M
10-Q · filed 2022-08-03
$12.42M
derived: sum of 3 quarters · filed 2024-02-21
$10.57M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31$8.00M
10-Q · filed 2023-05-09
$8.14M
10-Q · filed 2022-05-09
$8.42M
derived: sum of 2 quarters · filed 2024-02-21
$6.57M
derived: sum of 3 quarters · filed 2024-02-21
-$4.72M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$424.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
-$1.43M
derived: sum of 2 quarters · filed 2024-02-21
-$12.72M
derived: sum of 3 quarters · filed 2024-02-21
-$5.00M
10-K · filed 2024-02-21
-$4.77M
10-K · filed 2022-02-23
2021-09-30-$1.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
-$13.15M
derived: sum of 2 quarters · filed 2022-11-02
-$5.42M
10-Q · filed 2022-11-02
$411.00K
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$11.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
-$3.57M
10-Q · filed 2022-08-03
$2.27M
derived: sum of 3 quarters · filed 2023-02-28
-$1.24M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$7.72M
10-Q · filed 2022-05-09
$13.56M
derived: sum of 2 quarters · filed 2023-02-28
$10.05M
derived: sum of 3 quarters · filed 2023-02-28
$19.06M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$5.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$2.33M
derived: sum of 2 quarters · filed 2023-02-28
$11.34M
derived: sum of 3 quarters · filed 2023-02-28
$9.00M
10-K · filed 2023-02-28
$9.27M
10-K · filed 2021-02-25
2020-09-30-$3.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$5.51M
derived: sum of 2 quarters · filed 2021-11-08
$3.17M
10-Q · filed 2021-11-08
$4.99M
derived: sum of 4 quarters · filed 2022-02-23
2020-06-30$9.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$6.67M
10-Q · filed 2021-08-05
$8.49M
derived: sum of 3 quarters · filed 2022-02-23
$8.96M
derived: sum of 4 quarters · filed 2022-02-23
2020-03-31-$2.34M
10-Q · filed 2021-05-05
-$522.00K
derived: sum of 2 quarters · filed 2022-02-23
-$50.00K
derived: sum of 3 quarters · filed 2022-02-23
-$99.00K
derived: sum of 4 quarters · filed 2022-02-23
2019-12-31$1.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23
$2.29M
derived: sum of 2 quarters · filed 2022-02-23
$2.24M
derived: sum of 3 quarters · filed 2022-02-23
$1.73M
10-K · filed 2022-02-23
2019-09-30$472.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$423.00K
derived: sum of 2 quarters · filed 2020-11-05
-$94.00K
10-Q · filed 2020-11-05
$866.00K
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$49.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$566.00K
10-Q · filed 2020-08-06
$394.00K
derived: sum of 3 quarters · filed 2021-02-25
-$1.98M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$517.00K
10-Q · filed 2020-05-05
$443.00K
derived: sum of 2 quarters · filed 2021-02-25
-$1.93M
derived: sum of 3 quarters · filed 2021-02-25
-$280.00K
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$960.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$1.42M
derived: sum of 2 quarters · filed 2021-02-25
$237.00K
derived: sum of 3 quarters · filed 2021-02-25
-$69.00K
10-K · filed 2021-02-25
2018-09-30-$2.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
-$723.00K
derived: sum of 2 quarters · filed 2019-11-05
-$1.03M
10-Q · filed 2019-11-05
$1.01M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30$1.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$1.35M
10-Q · filed 2019-08-06
$3.39M
derived: sum of 3 quarters · filed 2019-08-06
$2.69M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31-$306.00K
10-Q · filed 2019-05-02
$1.73M
derived: sum of 2 quarters · filed 2019-05-02
$1.04M
derived: sum of 3 quarters · filed 2019-05-02
$2.12M
derived: sum of 4 quarters · filed 2019-05-02
2017-12-31$2.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05
$1.34M
derived: sum of 2 quarters · filed 2019-03-05
$2.42M
derived: sum of 3 quarters · filed 2019-03-05
-$267.00K
10-K · filed 2019-03-05
2017-09-30-$696.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$386.00K
derived: sum of 2 quarters · filed 2018-11-08
-$2.31M
10-Q · filed 2018-11-08
2017-06-30$1.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
-$1.61M
10-Q · filed 2018-08-06
2017-03-31-$2.69M
10-Q · filed 2018-05-09
2016-12-31$3.57M
10-K · filed 2019-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36